Clinical trials: Proof of Concept
Cellulite
Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite
Feasibility study is to evaluate the safety, tolerability and efficacy of Soliton's Rapid Acoustic Pulse (RAP) device for the treatment of cellulite
- Trial name
- NCT03981198
- Testing
- Soliton Rapid Acoustic Pulse (RAP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Soliton
Diabetes Mellitus, Type 2, Metabolic Syndrome X
A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes
The main objectives of the current study are to establish the safety and clinical proof-of-concept of NC-503 in inadequately controlled patients with Type 2 diabetes and features of metabolic syndrome treated with either…
- Trial name
- NCT00675857
- Testing
- NC-503 (eprodisate disodium)
- Where
- 21 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Bellus Health Inc. - a GSK company
Binge-Eating Disorder
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
- Trial name
- NCT04753164
- Testing
- ACT-539313
- Where
- 30 sites in United States
- Volunteers
- 136 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Atopic Dermatitis
An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side…
- Trial name
- NCT04922021
- Testing
- LEO 138559
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Cystic Fibrosis (CF)
Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
- Trial name
- PreciSION CF (NCT07108153)
- Testing
- SION-719
- Where
- 13 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Sionna Therapeutics Inc.
Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of VIB4920 (formerly MEDI4920) in adult participants with Sjögren's Syndrome (SS).
- Trial name
- SS (NCT04129164)
- Testing
- VIB4920
- Where
- 62 sites in United States, Argentina and 10 more
- Volunteers
- 183 people
- Sponsor
- Amgen
Painful Diabetic Peripheral Neuropathy
A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).
Diabetic peripheral neuropathy (DPN) represents a diffuse symmetric and length-dependent injury to peripheral nerves that has major implications on quality of life (QOL), morbidity, and costs from a public health perspective.
- Trial name
- NCT01726413
- Testing
- GRC 17356
- Where
- 15 sites in Czechia, Germany and 2 more
- Volunteers
- 138 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
Asthma
Study of SCH 527123 in Subjects With Severe Asthma (Study P05109AM1)
Given the strong inhibition of SCH 527123 on neutrophil migration to sites of inflammation, there is a theoretical reason for its use in patients with severe asthma where neutrophils are thought to play a significant role in the…
- Trial name
- NCT01006161
- Testing
- SCH 527123
- Sponsor
- Merck Sharp & Dohme LLC
Scleroderma, Diffuse, Diffuse Cutaneous Systemic Sclerosis
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences.
- Trial name
- FASST (NCT02503644)
- Testing
- IVA337
- Where
- 49 sites in Bulgaria, France and 8 more
- Volunteers
- 145 people
- Sponsor
- Inventiva Pharma
Colitis, Ulcerative
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
The objectives of this trial are safety and efficacy (proof-of-concept) of induction of mucosal healing by BI 655130 add-on therapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activity despite…
- Trial name
- NCT03123120
- Testing
- Spesolimab
- Where
- 16 sites in Denmark, Germany and 4 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Dentine Hypersensitivity
Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity.
- Trial name
- NCT01691560
- Testing
- 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice, 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice, Sodium monofluorophosphate dentifrice
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Post-traumatic Osteoarthritis of the Knee
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
This study was a double-blind, randomized, parallel group, proof of concept study comparing FX006 to Kenalog®-40 (triamcinolone acetonide injectable suspension, USP) in patients with post-traumatic osteoarthritis of the knee.
- Trial name
- NCT02468583
- Testing
- FX006 32 mg, TCA IR 40 mg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Primary Open Angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351
- Trial name
- NCT04448223
- Testing
- CKD-351, Latanoprost+Dorzolmamide
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Low Back Pain
RN624 In Adult Patients With Chronic Low Back Pain
The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.
- Trial name
- NCT00584870
- Testing
- Naproxen, PF-04383119 (RN624)
- Where
- 38 sites in United States
- Volunteers
- 220 people
- Sponsor
- Pfizer
Alzheimer's Disease
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease
This proof-of-concept study will assess safety, tolerance, and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer's Disease (AD).
- Trial name
- NanoLi®_AD (NCT05423522)
- Testing
- NanoLithium® NP03
- Where
- 8 sites in France
- Volunteers
- 72 people
- Sponsor
- Medesis Pharma SA
Scleroderma, Systemic
A Study of Guselkumab in Participants With Systemic Sclerosis
The purpose of the study is to evaluate the efficacy of guselkumab in participants with systemic sclerosis (SSc).
- Trial name
- NCT04683029
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2
- Where
- 4 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
Primary Dysmenorrhea
VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept
The purpose of the study is to investigate how effective VA111913 is at preventing menstrual pain in women with primary dysmenorrhoea.
- Trial name
- NCT00963053
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 146 people
- Sponsor
- Vantia Ltd
PreDiabetes, Aging
Safety and Efficacy of KH-1 for Stimulating Autophagy in Non-diabetic Adults With Elevated Blood Glucose Concentration
Aging significantly impacts overall health and is a risk factor for developing diabetes. An estimated 50% of U.S. adults aged ≥65 years were reported to have prediabetes (defined as having a fasting glucose concentration of…
- Trial name
- NCT06445569
- Testing
- KH-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Kalin Health, LLC